Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 10:00
10/04/22
10/04
10:00
10/04/22
10:00
GILD

Gilead

$64.21 /

+1.88 (+3.02%)

, DPZ

Domino's Pizza

$328.84 /

+12.485 (+3.95%)

, ILMN

Illumina

$201.32 /

+14.14 (+7.55%)

, COMM

CommScope

$10.95 /

+1.39 (+14.54%)

, BK

BNY Mellon

$41.08 /

+1.425 (+3.59%)

, PARA

Paramount

$19.77 /

+0.15 (+0.76%)

, SRAD

Sportradar

$8.45 /

-0.32 (-3.65%)

, MCG

Membership Collective

$3.47 /

-0.89 (-20.41%)

, MTB

M&T Bank

$184.94 /

+4.14 (+2.29%)

, WLK

Westlake

$91.80 /

+1.61 (+1.79%)

, AGTC

Applied Genetic

/

+

, SNX

TD Synnex

$86.77 /

+2.83 (+3.37%)

, GKOS

Glaukos

$55.96 /

+2.86 (+5.39%)

, DHX

DHI Group

$5.81 /

+0.165 (+2.93%)

, LFG

Archaea Energy

$19.93 /

+0.89 (+4.67%)

Institutional investors…

ShowHide Related Items >><<
WLK Westlake
$91.80 /

+1.61 (+1.79%)

SRAD Sportradar
$8.45 /

-0.32 (-3.65%)

SNX TD Synnex
$86.77 /

+2.83 (+3.37%)

PARA Paramount
$19.77 /

+0.15 (+0.76%)

MTB M&T Bank
$184.94 /

+4.14 (+2.29%)

MCG Membership Collective
$3.47 /

-0.89 (-20.41%)

LFG Archaea Energy
$19.93 /

+0.89 (+4.67%)

ILMN Illumina
$201.32 /

+14.14 (+7.55%)

GKOS Glaukos
$55.96 /

+2.86 (+5.39%)

GILD Gilead
$64.21 /

+1.88 (+3.02%)

DPZ Domino's Pizza
$328.84 /

+12.485 (+3.95%)

DHX DHI Group
$5.81 /

+0.165 (+2.93%)

COMM CommScope
$10.95 /

+1.39 (+14.54%)

BK BNY Mellon
$41.08 /

+1.425 (+3.59%)

AGTC Applied Genetic
/

+

GILD Gilead
$64.21 /

+1.88 (+3.02%)

06:35 Today JPMorgan
Gilead upgraded to Overweight from Neutral at JPMorgan
09/20/22 Piper Sandler
Piper says Merck partial hold being lifted a positive update for Gilead
09/15/22 Truist
Gilead price target raised to $76 from $71 at Truist
09/13/22 Wells Fargo
Gilead price target raised to $74 from $63 at Wells Fargo
DPZ Domino's Pizza
$328.84 /

+12.485 (+3.95%)

06:32 Today UBS
Domino's Pizza upgraded to Buy from Neutral at UBS
10/03/22 Oppenheimer
Domino's Pizza price target lowered to $415 from $445 at Oppenheimer
09/27/22 Cowen
Domino's Pizza price target lowered to $362 from $410 at Cowen
09/23/22 Citi
Domino's Pizza price target lowered to $415 from $475 at Citi
ILMN Illumina
$201.32 /

+14.14 (+7.55%)

08:59 Today SVB Securities
Illumina upgraded to Outperform from Market Perform at SVB Securities
06:25 Today Citi
Illumina long-term outlook in line with expectations, says Citi
09/30/22 Barclays
Illumina price target raised to $175 from $130 at Barclays
09/29/22 Piper Sandler
Piper says Illumina remains a top pick after NovaSeq X unveil
COMM CommScope
$10.95 /

+1.39 (+14.54%)

05:49 Today Credit Suisse
CommScope upgraded to Outperform from Neutral at Credit Suisse
08/05/22 Deutsche Bank
CommScope price target raised to $12 from $9 at Deutsche Bank
08/05/22 Citi
CommScope price target raised to $7 from $6 at Citi
08/05/22 Morgan Stanley
CommScope downgraded to Equal Weight from Overweight at Morgan Stanley
BK BNY Mellon
$41.08 /

+1.425 (+3.59%)

05:57 Today Citi
BNY Mellon upgraded to Buy from Neutral at Citi
05:55 Today Citi
BNY Mellon upgraded to Buy from Neutral at Citi
09/27/22 Deutsche Bank
BNY Mellon price target lowered to $44 from $46 at Deutsche Bank
08/12/22 Deutsche Bank
BNY Mellon price target raised to $46 from $42 at Deutsche Bank
PARA Paramount
$19.77 /

+0.15 (+0.76%)

06:49 Today Wells Fargo
Wells Fargo downgrades Paramount on 'crumbling' linear ecosystem
05:12 Today Wells Fargo
Paramount downgraded to Equal Weight from Overweight at Wells Fargo
08/15/22 Benchmark
Nexstar getting 75% stake in CW Network for 'free,' says Benchmark
08/05/22 Deutsche Bank
Paramount price target lowered to $32 from $35 at Deutsche Bank
SRAD Sportradar
$8.45 /

-0.32 (-3.65%)

08:48 Today BofA
Sportradar downgraded to Underperform from Neutral at BofA
08:40 Today BofA
Sportradar downgraded to Underperform from Neutral at BofA
08/18/22 Canaccord
Sportradar price target raised to $20 from $18 at Canaccord
08/18/22 Deutsche Bank
Sportradar price target raised to $16 from $13 at Deutsche Bank
MCG Membership Collective
$3.47 /

-0.89 (-20.41%)

08:51 Today BofA
Membership Collective double downgraded to Underperform from Buy at BofA
08:46 Today BofA
Membership Collective downgraded to Underperform from Buy at BofA
08/18/22 Citi
Membership Collective post-earnings selloff unjustified, says Citi
03/28/22 Citi
Membership Collective price target lowered to $14 from $18 at Citi
MTB M&T Bank
$184.94 /

+4.14 (+2.29%)

05:59 Today Citi
M&T Bank downgraded to Neutral from Buy at Citi
05:55 Today Citi
M&T Bank downgraded to Neutral from Buy at Citi
09/30/22 Citi
Citi removes three from North America Focus List, adds KLA Corp.
09/28/22 Wedbush
M&T Bank assumed with a Neutral at Wedbush
WLK Westlake
$91.80 /

+1.61 (+1.79%)

08:02 Today Citi
Westlake downgraded to Sell on slowing housing market at Citi
07:33 Today Citi
Westlake downgraded to Sell from Neutral at Citi
06:27 Today KeyBanc
Westlake price target lowered to $79 from $90 at KeyBanc
10/03/22 Credit Suisse
Westlake price target lowered to $110 from $120 at Credit Suisse
AGTC Applied Genetic
/

+

06:45 Today Wells Fargo
Applied Genetic downgraded to Equal Weight from Overweight at Wells Fargo
09/30/22 Stifel
Applied Genetic price target lowered to $3 from $10 at Stifel
09/30/22 H.C. Wainwright
Applied Genetic price target lowered to $16 from $24 at H.C. Wainwright
09/28/22 BTIG
Applied Genetic downgraded to Neutral from Buy at BTIG
SNX TD Synnex
$86.77 /

+2.83 (+3.37%)

06:19 Today RBC Capital
TD Synnex initiated with a Sector Perform at RBC Capital
09/28/22 Barrington
TD Synnex price target lowered to $98 from $106 at Barrington
09/28/22 Raymond James
TD Synnex price target lowered to $140 from $175 at Raymond James
09/27/22 Credit Suisse
TD Synnex price target lowered to $103 from $110 at Credit Suisse
GKOS Glaukos
$55.96 /

+2.86 (+5.39%)

07:31 Today Needham
Needham starts Glaukos at Buy, expects recent launches to drive share recovery
06:16 Today Needham
Glaukos initiated with a Buy at Needham
09/07/22 Piper Sandler
Glaukos shares reflect constructive iDose view, says Piper Sandler
08/04/22 Citi
Glaukos price target raised to $54 from $49 at Citi
DHX DHI Group
$5.81 /

+0.165 (+2.93%)

09:04 Today Barrington
DHI Group initiated with an Outperform at Barrington
05/05/22 B. Riley
DHI Group price target raised to $9 from $8.50 at B. Riley
02/09/22 B. Riley
DHI Group price target raised to $8.50 from $7.50 at B. Riley
01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
LFG Archaea Energy
$19.93 /

+0.89 (+4.67%)

06:44 Today Wells Fargo
Archaea Energy initiated with an Overweight at Wells Fargo
06/17/22 Barclays
Barclays starts Archaea Energy at Overweight on 'vast' growth potential
06/17/22 Barclays
Archaea Energy initiated with an Overweight at Barclays
03/07/22 Stifel
Archaea Energy initiated with a Buy and placed on Select List at Stifel
WLK Westlake
$91.80 /

+1.61 (+1.79%)

SRAD Sportradar
$8.45 /

-0.32 (-3.65%)

SNX TD Synnex
$86.77 /

+2.83 (+3.37%)

PARA Paramount
$19.77 /

+0.15 (+0.76%)

MTB M&T Bank
$184.94 /

+4.14 (+2.29%)

MCG Membership Collective
$3.47 /

-0.89 (-20.41%)

LFG Archaea Energy
$19.93 /

+0.89 (+4.67%)

ILMN Illumina
$201.32 /

+14.14 (+7.55%)

GKOS Glaukos
$55.96 /

+2.86 (+5.39%)

GILD Gilead
$64.21 /

+1.88 (+3.02%)

DPZ Domino's Pizza
$328.84 /

+12.485 (+3.95%)

DHX DHI Group
$5.81 /

+0.165 (+2.93%)

COMM CommScope
$10.95 /

+1.39 (+14.54%)

BK BNY Mellon
$41.08 /

+1.425 (+3.59%)

  • 14
    Jul
  • 23
    Mar
  • 22
    Mar
PARA Paramount
$19.77 /

+0.15 (+0.76%)

ILMN Illumina
$201.32 /

+14.14 (+7.55%)

WLK Westlake
$91.80 /

+1.61 (+1.79%)

SRAD Sportradar
$8.45 /

-0.32 (-3.65%)

SNX TD Synnex
$86.77 /

+2.83 (+3.37%)

PARA Paramount
$19.77 /

+0.15 (+0.76%)

MTB M&T Bank
$184.94 /

+4.14 (+2.29%)

MCG Membership Collective
$3.47 /

-0.89 (-20.41%)

LFG Archaea Energy
$19.93 /

+0.89 (+4.67%)

ILMN Illumina
$201.32 /

+14.14 (+7.55%)

GKOS Glaukos
$55.96 /

+2.86 (+5.39%)

GILD Gilead
$64.21 /

+1.88 (+3.02%)

DPZ Domino's Pizza
$328.84 /

+12.485 (+3.95%)

DHX DHI Group
$5.81 /

+0.165 (+2.93%)

COMM CommScope
$10.95 /

+1.39 (+14.54%)

BK BNY Mellon
$41.08 /

+1.425 (+3.59%)

AGTC Applied Genetic
/

+

PARA Paramount
$19.77 /

+0.15 (+0.76%)

ILMN Illumina
$201.32 /

+14.14 (+7.55%)

GILD Gilead
$64.21 /

+1.88 (+3.02%)

DPZ Domino's Pizza
$328.84 /

+12.485 (+3.95%)

BK BNY Mellon
$41.08 /

+1.425 (+3.59%)

Hot Stocks
Clearside Biomedical's SCS platform featured in presentations at AAO meeting » 07:21
10/04/22
10/04
07:21
10/04/22
07:21
CLSD

Clearside Biomedical

$1.19 /

+0.05 (+4.39%)

, AURA

Aura Biosciences

$14.69 /

-3.51 (-19.29%)

, RGNX

Regenxbio

$24.17 /

-2.29 (-8.65%)

Clearside Biomedical…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RGNX Regenxbio
$24.17 /

-2.29 (-8.65%)

CLSD Clearside Biomedical
$1.19 /

+0.05 (+4.39%)

AURA Aura Biosciences
$14.69 /

-3.51 (-19.29%)

CLSD Clearside Biomedical
$1.19 /

+0.05 (+4.39%)

08/10/22 H.C. Wainwright
Clearside Biomedical price target lowered to $5 from $10 at H.C. Wainwright
12/22/21 Roth Capital
Roth says Clearside data 'certainly supportive' of dose-escalation in Wet AMD
12/21/21 JMP Securities
JMP remains bullish on Clearside as Cohort 2 in OASIS adds to CLS-AX potential
12/15/21 Wedbush
Clearside Biomedical assumed with an Outperform at Wedbush
AURA Aura Biosciences
$14.69 /

-3.51 (-19.29%)

07/19/22 JMP Securities
Aura Biosciences initiated with an Outperform at JMP Securities
11/23/21 SVB Securities
Aura Biosciences initiated with an Outperform at SVB Leerink
11/23/21 BTIG
Aura Biosciences initiated with a Buy at BTIG
11/23/21 Evercore ISI
Evercore starts Aura Biosciences at Outperform with $35 price target
RGNX Regenxbio
$24.17 /

-2.29 (-8.65%)

06:41 Today RBC Capital
Regenxbio price target lowered to $29 from $47 at RBC Capital
06/23/22 Berenberg
Regenxbio initiated with a Buy at Berenberg
06/23/22 UBS
Regenxbio price target lowered to $47 from $51 at UBS
03/29/22 Chardan
Regenxbio price target lowered to $76 from $90 at Chardan
RGNX Regenxbio
$24.17 /

-2.29 (-8.65%)

CLSD Clearside Biomedical
$1.19 /

+0.05 (+4.39%)

AURA Aura Biosciences
$14.69 /

-3.51 (-19.29%)

  • 29
    Oct
AURA Aura Biosciences
$14.69 /

-3.51 (-19.29%)

Downgrade
Applied Genetic downgraded to Equal Weight from Overweight at Wells Fargo » 06:45
10/04/22
10/04
06:45
10/04/22
06:45
AGTC

Applied Genetic

/

+

Wells Fargo analyst Yanan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AGTC Applied Genetic
/

+

AGTC Applied Genetic
/

+

09/30/22 Stifel
Applied Genetic price target lowered to $3 from $10 at Stifel
09/30/22 H.C. Wainwright
Applied Genetic price target lowered to $16 from $24 at H.C. Wainwright
09/28/22 BTIG
Applied Genetic downgraded to Neutral from Buy at BTIG
09/28/22 Chardan
Applied Genetic price target lowered to $3 from $5 at Chardan
  • 14
    Jul
  • 22
    Mar
AGTC Applied Genetic
/

+

Sunday
Hot Stocks
Belite Bio presents 12-month interim results of LBS-008 Phase 1b/2 study » 09:35
10/02/22
10/02
09:35
10/02/22
09:35
BLTE

Belite Bio

$33.88 /

+1.05 (+3.20%)

Belite Bio presented…

Belite Bio presented one-year data from their ongoing two-year Phase 2 clinical study of Tinlarebant in STGD1 as part of the oral presentation series at the Annual Meeting of the American Academy of Ophthalmology. To date, all 13 patients have completed one-year of treatment in the ongoing two-year Phase 2 study of Tinlarebant. The results for safety and tolerability assessments, and retinal imaging data have been collected for the evaluation of disease progression. Images from spectral-domain optical coherence tomography imaging, an imaging modality that permits visualization of the retinal anatomy, have shown a stabilization of retinal thickness in many subjects. Fundus autofluorescence imaging shows no autofluorescence expansion in 7 of 13 subjects, and 12 of 13 subjects also show no atrophic lesion after one year of treatment. More importantly, 9 of 13 subjects show a stabilization or improvement in visual acuity throughout the one-year treatment period. Belite Bio is currently conducting a two-year Phase 2 study and a two-year Phase 3 study of Tinlarebant in adolescent STGD1 subjects. Belite Bio expects the next data readout in its Phase 2 STGD1 study to occur during the second quarter of 2023 when all subjects will complete 18 months of treatment.

ShowHide Related Items >><<
BLTE Belite Bio
$33.88 /

+1.05 (+3.20%)

BLTE Belite Bio
$33.88 /

+1.05 (+3.20%)

08/01/22 H.C. Wainwright
Belite Bio initiated with a Buy at H.C. Wainwright
07/01/22 Benchmark
Belite Bio initiated with a Buy at Benchmark
  • 29
    Apr
BLTE Belite Bio
$33.88 /

+1.05 (+3.20%)

Friday
Recommendations
Applied Genetic price target lowered to $3 from $10 at Stifel » 07:26
09/30/22
09/30
07:26
09/30/22
07:26
AGTC

Applied Genetic

/

+

Stifel analyst Dae Gon Ha…

Stifel analyst Dae Gon Ha lowered the firm's price target on Applied Genetic to $3 from $10 and keeps a Buy rating on the shares, stating after reviewing the company's 10K that he cannot definitively rule out nondilutive financing opportunities arising from partnerships and/or business development activities. However, for now, he is reducing his view on the probability of success and delaying launch projections to reflect "a less sanguine outlook on the company's pipeline endeavors," Gon Ha said.

ShowHide Related Items >><<
AGTC Applied Genetic
/

+

AGTC Applied Genetic
/

+

09/30/22 H.C. Wainwright
Applied Genetic price target lowered to $16 from $24 at H.C. Wainwright
09/28/22 BTIG
Applied Genetic downgraded to Neutral from Buy at BTIG
09/28/22 Chardan
Applied Genetic price target lowered to $3 from $5 at Chardan
06/28/22 H.C. Wainwright
H.C. Wainwright says Applied's AGTC-501 'remains leader' after MeiraGTx data
  • 14
    Jul
  • 22
    Mar
AGTC Applied Genetic
/

+

Recommendations
Applied Genetic price target lowered to $16 from $24 at H.C. Wainwright » 06:10
09/30/22
09/30
06:10
09/30/22
06:10
AGTC

Applied Genetic

/

+

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Applied Genetic Technologies to $16 from $24 and keeps a Buy rating on the shares post the fiscal 2022 results.

ShowHide Related Items >><<
AGTC Applied Genetic
/

+

AGTC Applied Genetic
/

+

09/28/22 BTIG
Applied Genetic downgraded to Neutral from Buy at BTIG
09/28/22 Chardan
Applied Genetic price target lowered to $3 from $5 at Chardan
06/28/22 H.C. Wainwright
H.C. Wainwright says Applied's AGTC-501 'remains leader' after MeiraGTx data
03/29/22 Chardan
Applied Genetic transferred with Buy rating at Chardan
  • 14
    Jul
  • 22
    Mar
AGTC Applied Genetic
/

+

Thursday
Hot Stocks
EyePoint announces first patient dosed in Phase 2 PAVIA trial of EYP-1901 » 07:13
09/29/22
09/29
07:13
09/29/22
07:13
EYPT

EyePoint

$7.65 /

+0.645 (+9.21%)

EyePoint Pharmaceuticals…

EyePoint Pharmaceuticals announced that the first patient has been dosed in the Phase 2 PAVIA clinical trial of EYP-1901, a potential sustained delivery intravitreal anti-vascular endothelial growth factor treatment targeting non-proliferative diabetic retinopathy. "We are excited to announce the first patient dosing of the Phase 2 PAVIA clinical trial of EYP-1901 for NPDR, a serious eye disorder affecting almost one-third of adults over the age of 40 with diabetes that can lead to severe vision loss if left uncontrolled," said Jay Duker, M.D., Chief Operating Officer of EyePoint Pharmaceuticals. "Despite the severe nature of this disease, the current standard-of-care is no treatment until a patient develops sight-threatening complications. There remains a lack of approved treatments for this serious eye disease, leaving a significant opportunity for a long-acting treatment option that maintains the patient's existing vision proactively. Building on EYP-1901's excellent safety and efficacy results from our Phase 1 DAVIO trial in wet AMD, we believe that EYP-1901 has the potential to improve the current treatment paradigm as a sustained delivery maintenance treatment for NPDR and significantly improve the lives of patients living with this serious eye disorder."

ShowHide Related Items >><<
EYPT EyePoint
$7.65 /

+0.645 (+9.21%)

EYPT EyePoint
$7.65 /

+0.645 (+9.21%)

08/31/22 Cantor Fitzgerald
Cantor says EyePoint negative stock reaction to 8-K 'overdone'
08/04/22 H.C. Wainwright
EyePoint price target raised to $25 from $24 at H.C. Wainwright
07/07/22 Chardan
EyePoint initiated with a Buy at Chardan
11/16/21 Cantor Fitzgerald
EyePoint stock movement unwarranted, says Cantor Fitzgerald
EYPT EyePoint
$7.65 /

+0.645 (+9.21%)

  • 17
    Nov
Conference/Events
Guggenheim to hold a conference » 04:55
09/29/22
09/29
04:55
09/29/22
04:55
RPTX

Repare Therapeutics

$12.42 /

+0.56 (+4.72%)

, IMGN

ImmunoGen

$4.72 /

+0.08 (+1.72%)

, CNTA

Centessa

$4.62 /

+0.115 (+2.55%)

, KYMR

Kymera Therapeutics

$22.72 /

+1.1 (+5.09%)

, MGNX

MacroGenics

$3.65 /

+0.155 (+4.44%)

, SEEL

Seelos Therapeutics

$1.17 /

+0.12 (+11.43%)

, GLUE

Monte Rosa Therapeutics

$8.34 /

+0.575 (+7.41%)

, NTLA

Intellia Therapeutics

$58.66 /

+2.585 (+4.61%)

, EYPT

EyePoint

$7.65 /

+0.645 (+9.21%)

, IMPL

Impel Pharmaceuticals

$5.67 /

+0.24 (+4.42%)

, RUBY

Rubius Therapeutics

/

+

Nantucket Therapeutics…

Nantucket Therapeutics Conference to be held in New York on September 27-29. Webcast Link

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$1.17 /

+0.12 (+11.43%)

RUBY Rubius Therapeutics
/

+

RPTX Repare Therapeutics
$12.42 /

+0.56 (+4.72%)

NTLA Intellia Therapeutics
$58.66 /

+2.585 (+4.61%)

MGNX MacroGenics
$3.65 /

+0.155 (+4.44%)

KYMR Kymera Therapeutics
$22.72 /

+1.1 (+5.09%)

IMPL Impel Pharmaceuticals
$5.67 /

+0.24 (+4.42%)

IMGN ImmunoGen
$4.72 /

+0.08 (+1.72%)

GLUE Monte Rosa Therapeutics
$8.34 /

+0.575 (+7.41%)

EYPT EyePoint
$7.65 /

+0.645 (+9.21%)

CNTA Centessa
$4.62 /

+0.115 (+2.55%)

RPTX Repare Therapeutics
$12.42 /

+0.56 (+4.72%)

06/06/22 H.C. Wainwright
Repare Therapeutics price target lowered to $38 from $54 at H.C. Wainwright
06/02/22 Piper Sandler
Piper ups Repare Therapeutics target after 'great deal' with Roche
04/12/22 Stifel
Stifel downgrades Repare Therapeutics after 'blow to synthetic lethality thesis'
04/12/22 Stifel
Repare Therapeutics downgraded to Hold from Buy at Stifel
IMGN ImmunoGen
$4.72 /

+0.08 (+1.72%)

09/09/22 Barclays
ImmunoGen initiated with an Overweight at Barclays
08/31/22 Piper Sandler
Piper pushes launch estimates for ImmunoGen's pivekimab out by year after update
08/18/22 Wells Fargo
Sutro Biopharma assumed with an Overweight at Wells Fargo
03/21/22 RBC Capital
ImmunoGen downgraded to Sector Perform from Outperform at RBC Capital
CNTA Centessa
$4.62 /

+0.115 (+2.55%)

08/12/22 Morgan Stanley
Centessa double downgraded to Underweight from Overweight at Morgan Stanley
08/12/22 Morgan Stanley
Centessa downgraded to Underweight from Overweight at Morgan Stanley
08/11/22 BMO Capital
Centessa price target lowered to $11 from $19 at BMO Capital
06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
KYMR Kymera Therapeutics
$22.72 /

+1.1 (+5.09%)

08/31/22 JPMorgan
Kymera selloff a 'misplaced knee-jerk reaction,' says JPMorgan
08/15/22 Jefferies
Kymera Therapeutics initiated with a Buy at Jefferies
08/03/22 Goldman Sachs
Kymera Therapeutics initiated with a Buy at Goldman Sachs
07/20/22 SVB Securities
Kymera Therapeutics initiated with a Market Perform at SVB Securities
MGNX MacroGenics
$3.65 /

+0.155 (+4.44%)

09/12/22 H.C. Wainwright
MacroGenics price target lowered to $10 from $35 at H.C. Wainwright
08/29/22 Citi
MacroGenics price target raised to $16 from $13 at Citi
08/09/22 Barclays
MacroGenics price target lowered to $8 from $18 at Barclays
07/11/22 BTIG
MacroGenics price target lowered to $6 at BTIG
SEEL Seelos Therapeutics
$1.17 /

+0.12 (+11.43%)

03/14/22 B. Riley
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley
03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
GLUE Monte Rosa Therapeutics
$8.34 /

+0.575 (+7.41%)

08/15/22 Jefferies
Monte Rosa Therapeutics initiated with a Buy at Jefferies
05/11/22 Piper Sandler
Monte Rosa Therapeutics price target lowered to $21 from $40 at Piper Sandler
04/28/22 Credit Suisse
Monte Rosa Therapeutics initiated with a Neutral at Credit Suisse
04/08/22 Piper Sandler
Piper keeps Overweight rating on Monte Rosa Therapeutics after AACR abstract
NTLA Intellia Therapeutics
$58.66 /

+2.585 (+4.61%)

09/21/22 JPMorgan
JPMorgan starts Intellia with Overweight, adds to Focus List
09/21/22 JPMorgan
Intellia Therapeutics initiated with an Overweight at JPMorgan
09/19/22 JMP Securities
Intellia Therapeutics price target raised to $111 from $106 at JMP Securities
09/19/22 Citi
Citi keeps Sell rating, $50 target on Intellia Therapeutics after data
EYPT EyePoint
$7.65 /

+0.645 (+9.21%)

08/31/22 Cantor Fitzgerald
Cantor says EyePoint negative stock reaction to 8-K 'overdone'
08/04/22 H.C. Wainwright
EyePoint price target raised to $25 from $24 at H.C. Wainwright
07/07/22 Chardan
EyePoint initiated with a Buy at Chardan
11/16/21 Cantor Fitzgerald
EyePoint stock movement unwarranted, says Cantor Fitzgerald
IMPL Impel Pharmaceuticals
$5.67 /

+0.24 (+4.42%)

08/24/22 JonesTrading
Impel Pharmaceuticals initiated with a Buy at JonesTrading
RUBY Rubius Therapeutics
/

+

09/13/22 Guggenheim
Rubius downgraded at Guggenheim after discontinuation of all clinical programs
09/13/22 Guggenheim
Rubius Therapeutics downgraded to Neutral from Buy at Guggenheim
05/11/22 H.C. Wainwright
Rubius Therapeutics price target lowered to $8 from $15 at H.C. Wainwright
04/11/22 Morgan Stanley
Rubius Therapeutics price target lowered to $4 from $15 at Morgan Stanley
RUBY Rubius Therapeutics
/

+

RPTX Repare Therapeutics
$12.42 /

+0.56 (+4.72%)

NTLA Intellia Therapeutics
$58.66 /

+2.585 (+4.61%)

MGNX MacroGenics
$3.65 /

+0.155 (+4.44%)

KYMR Kymera Therapeutics
$22.72 /

+1.1 (+5.09%)

IMPL Impel Pharmaceuticals
$5.67 /

+0.24 (+4.42%)

IMGN ImmunoGen
$4.72 /

+0.08 (+1.72%)

GLUE Monte Rosa Therapeutics
$8.34 /

+0.575 (+7.41%)

EYPT EyePoint
$7.65 /

+0.645 (+9.21%)

CNTA Centessa
$4.62 /

+0.115 (+2.55%)

  • 02
    Dec
  • 17
    Nov
  • 28
    Oct
NTLA Intellia Therapeutics
$58.66 /

+2.585 (+4.61%)

RPTX Repare Therapeutics
$12.42 /

+0.56 (+4.72%)

NTLA Intellia Therapeutics
$58.66 /

+2.585 (+4.61%)

KYMR Kymera Therapeutics
$22.72 /

+1.1 (+5.09%)

IMPL Impel Pharmaceuticals
$5.67 /

+0.24 (+4.42%)

CNTA Centessa
$4.62 /

+0.115 (+2.55%)

SEEL Seelos Therapeutics
$1.17 /

+0.12 (+11.43%)

GLUE Monte Rosa Therapeutics
$8.34 /

+0.575 (+7.41%)

CNTA Centessa
$4.62 /

+0.115 (+2.55%)

Wednesday
Downgrade
Applied Genetic downgraded to Neutral from Buy at BTIG » 18:22
09/28/22
09/28
18:22
09/28/22
18:22
AGTC

Applied Genetic

/

+

, BIIB

Biogen

$276.59 /

+78.74 (+39.80%)

BTIG analyst Yun Zhong…

BTIG analyst Yun Zhong downgraded Applied Genetic (AGTC) to Neutral from Buy. The company has reported a stronger dataset than competitors that are developing similar AAV gene therapy programs for the same indication, and the stock is trading below cash with approximately 67.6M shares outstanding as of September 21, the analyst tells investors in a research note, also noting that Biogen's (BIIB) Alzheimer's disease data yesterday provided a strong lift for the entire biotech sector. Zhong adds however that the significant uncertainty created by the cash overhang for Applied Genetic, which has only $67.8M as of the end of Q3, suggests that a more prudent approach should be to remove the AGTC-501 program from valuation at this moment.

ShowHide Related Items >><<
BIIB Biogen
$276.59 /

+78.74 (+39.80%)

AGTC Applied Genetic
/

+

AGTC Applied Genetic
/

+

09/28/22 Chardan
Applied Genetic price target lowered to $3 from $5 at Chardan
06/28/22 H.C. Wainwright
H.C. Wainwright says Applied's AGTC-501 'remains leader' after MeiraGTx data
03/29/22 Chardan
Applied Genetic transferred with Buy rating at Chardan
02/14/22 Stifel
Stifel keeps Buy rating on Applied Genetic, lowers price target to $10
BIIB Biogen
$276.59 /

+78.74 (+39.80%)

09/28/22 Morgan Stanley
Eisai upgraded to Equal Weight at Morgan Stanley after lecanemab success
09/28/22 BofA
Prothena upgraded at BofA as Biogen data seen strengthening amyloid thesis
09/28/22 Needham
Path for Biogen's lecanemab to be 'multi-step' process, says Needham
09/28/22 RBC Capital
Biogen price target raised to $321 from $251 at RBC Capital
BIIB Biogen
$276.59 /

+78.74 (+39.80%)

  • 14
    Jul
  • 22
    Mar
BIIB Biogen
$276.59 /

+78.74 (+39.80%)

AGTC Applied Genetic
/

+

BIIB Biogen
$276.59 /

+78.74 (+39.80%)

Conference/Events
Guggenheim to hold a conference » 11:40
09/28/22
09/28
11:40
09/28/22
11:40
RPTX

Repare Therapeutics

$12.37 /

+0.51 (+4.30%)

, IMGN

ImmunoGen

$4.69 /

+0.05 (+1.08%)

, CNTA

Centessa

$4.55 /

+0.045 (+1.00%)

, KYMR

Kymera Therapeutics

$22.24 /

+0.62 (+2.87%)

, MGNX

MacroGenics

$3.64 /

+0.15 (+4.30%)

, SEEL

Seelos Therapeutics

$1.12 /

+0.07 (+6.67%)

, GLUE

Monte Rosa Therapeutics

$8.29 /

+0.525 (+6.76%)

, NTLA

Intellia Therapeutics

$57.48 /

+1.405 (+2.51%)

, EYPT

EyePoint

$7.38 /

+0.375 (+5.35%)

, IMPL

Impel Pharmaceuticals

$5.65 /

+0.22 (+4.05%)

, RUBY

Rubius Therapeutics

/

+

Nantucket Therapeutics…

Nantucket Therapeutics Conference to be held in New York on September 27-29. Webcast Link

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$1.12 /

+0.07 (+6.67%)

RUBY Rubius Therapeutics
/

+

RPTX Repare Therapeutics
$12.37 /

+0.51 (+4.30%)

NTLA Intellia Therapeutics
$57.48 /

+1.405 (+2.51%)

MGNX MacroGenics
$3.64 /

+0.15 (+4.30%)

KYMR Kymera Therapeutics
$22.24 /

+0.62 (+2.87%)

IMPL Impel Pharmaceuticals
$5.65 /

+0.22 (+4.05%)

IMGN ImmunoGen
$4.69 /

+0.05 (+1.08%)

GLUE Monte Rosa Therapeutics
$8.29 /

+0.525 (+6.76%)

EYPT EyePoint
$7.38 /

+0.375 (+5.35%)

CNTA Centessa
$4.55 /

+0.045 (+1.00%)

RPTX Repare Therapeutics
$12.37 /

+0.51 (+4.30%)

06/06/22 H.C. Wainwright
Repare Therapeutics price target lowered to $38 from $54 at H.C. Wainwright
06/02/22 Piper Sandler
Piper ups Repare Therapeutics target after 'great deal' with Roche
04/12/22 Stifel
Stifel downgrades Repare Therapeutics after 'blow to synthetic lethality thesis'
04/12/22 Stifel
Repare Therapeutics downgraded to Hold from Buy at Stifel
IMGN ImmunoGen
$4.69 /

+0.05 (+1.08%)

09/09/22 Barclays
ImmunoGen initiated with an Overweight at Barclays
08/31/22 Piper Sandler
Piper pushes launch estimates for ImmunoGen's pivekimab out by year after update
08/18/22 Wells Fargo
Sutro Biopharma assumed with an Overweight at Wells Fargo
03/21/22 RBC Capital
ImmunoGen downgraded to Sector Perform from Outperform at RBC Capital
CNTA Centessa
$4.55 /

+0.045 (+1.00%)

08/12/22 Morgan Stanley
Centessa double downgraded to Underweight from Overweight at Morgan Stanley
08/12/22 Morgan Stanley
Centessa downgraded to Underweight from Overweight at Morgan Stanley
08/11/22 BMO Capital
Centessa price target lowered to $11 from $19 at BMO Capital
06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
KYMR Kymera Therapeutics
$22.24 /

+0.62 (+2.87%)

08/31/22 JPMorgan
Kymera selloff a 'misplaced knee-jerk reaction,' says JPMorgan
08/15/22 Jefferies
Kymera Therapeutics initiated with a Buy at Jefferies
08/03/22 Goldman Sachs
Kymera Therapeutics initiated with a Buy at Goldman Sachs
07/20/22 SVB Securities
Kymera Therapeutics initiated with a Market Perform at SVB Securities
MGNX MacroGenics
$3.64 /

+0.15 (+4.30%)

09/12/22 H.C. Wainwright
MacroGenics price target lowered to $10 from $35 at H.C. Wainwright
08/29/22 Citi
MacroGenics price target raised to $16 from $13 at Citi
08/09/22 Barclays
MacroGenics price target lowered to $8 from $18 at Barclays
07/11/22 BTIG
MacroGenics price target lowered to $6 at BTIG
SEEL Seelos Therapeutics
$1.12 /

+0.07 (+6.67%)

03/14/22 B. Riley
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley
03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
GLUE Monte Rosa Therapeutics
$8.29 /

+0.525 (+6.76%)

08/15/22 Jefferies
Monte Rosa Therapeutics initiated with a Buy at Jefferies
05/11/22 Piper Sandler
Monte Rosa Therapeutics price target lowered to $21 from $40 at Piper Sandler
04/28/22 Credit Suisse
Monte Rosa Therapeutics initiated with a Neutral at Credit Suisse
04/08/22 Piper Sandler
Piper keeps Overweight rating on Monte Rosa Therapeutics after AACR abstract
NTLA Intellia Therapeutics
$57.48 /

+1.405 (+2.51%)

09/21/22 JPMorgan
JPMorgan starts Intellia with Overweight, adds to Focus List
09/21/22 JPMorgan
Intellia Therapeutics initiated with an Overweight at JPMorgan
09/19/22 JMP Securities
Intellia Therapeutics price target raised to $111 from $106 at JMP Securities
09/19/22 Citi
Citi keeps Sell rating, $50 target on Intellia Therapeutics after data
EYPT EyePoint
$7.38 /

+0.375 (+5.35%)

08/31/22 Cantor Fitzgerald
Cantor says EyePoint negative stock reaction to 8-K 'overdone'
08/04/22 H.C. Wainwright
EyePoint price target raised to $25 from $24 at H.C. Wainwright
07/07/22 Chardan
EyePoint initiated with a Buy at Chardan
11/16/21 Cantor Fitzgerald
EyePoint stock movement unwarranted, says Cantor Fitzgerald
IMPL Impel Pharmaceuticals
$5.65 /

+0.22 (+4.05%)

08/24/22 JonesTrading
Impel Pharmaceuticals initiated with a Buy at JonesTrading
RUBY Rubius Therapeutics
/

+

09/13/22 Guggenheim
Rubius downgraded at Guggenheim after discontinuation of all clinical programs
09/13/22 Guggenheim
Rubius Therapeutics downgraded to Neutral from Buy at Guggenheim
05/11/22 H.C. Wainwright
Rubius Therapeutics price target lowered to $8 from $15 at H.C. Wainwright
04/11/22 Morgan Stanley
Rubius Therapeutics price target lowered to $4 from $15 at Morgan Stanley
RUBY Rubius Therapeutics
/

+

RPTX Repare Therapeutics
$12.37 /

+0.51 (+4.30%)

NTLA Intellia Therapeutics
$57.48 /

+1.405 (+2.51%)

MGNX MacroGenics
$3.64 /

+0.15 (+4.30%)

KYMR Kymera Therapeutics
$22.24 /

+0.62 (+2.87%)

IMPL Impel Pharmaceuticals
$5.65 /

+0.22 (+4.05%)

IMGN ImmunoGen
$4.69 /

+0.05 (+1.08%)

GLUE Monte Rosa Therapeutics
$8.29 /

+0.525 (+6.76%)

EYPT EyePoint
$7.38 /

+0.375 (+5.35%)

CNTA Centessa
$4.55 /

+0.045 (+1.00%)

  • 02
    Dec
  • 17
    Nov
  • 28
    Oct
NTLA Intellia Therapeutics
$57.48 /

+1.405 (+2.51%)

RPTX Repare Therapeutics
$12.37 /

+0.51 (+4.30%)

NTLA Intellia Therapeutics
$57.48 /

+1.405 (+2.51%)

KYMR Kymera Therapeutics
$22.24 /

+0.62 (+2.87%)

IMPL Impel Pharmaceuticals
$5.65 /

+0.22 (+4.05%)

CNTA Centessa
$4.55 /

+0.045 (+1.00%)

SEEL Seelos Therapeutics
$1.12 /

+0.07 (+6.67%)

GLUE Monte Rosa Therapeutics
$8.29 /

+0.525 (+6.76%)

CNTA Centessa
$4.55 /

+0.045 (+1.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.